NCT06768515

Brief Summary

Solid organ transplantation is the treatment of choice for end stage organ failure to improve patients' quality of life and survival. Each year, more than 5,000 solid organ transplants are performed in France, mainly from brain death donors (BDD). Approximately 1,500 BDD donors have one or more organs removed each year. Despite the growing demand for transplanted organs, the number of organs available from deceased donors has remained stable over the past few decades. This highlights the need to optimize the management of potential BDD, in order to increase both the quality and number of transplanted organs. Several studies have found an association between the characteristics and management of BDD donors and the number of organs, or even the function of transplanted organs. Data suggest that hemodynamic, respiratory, and metabolic therapeutic targets during BDD management prior to multi-organ procurement were associated with a higher number of transplanted organs compared to standard care. However, this has never been confirmed in a French population. Furthermore, while the impact of these therapeutic goals has been studied after the donor is in a state of brain death, the events occurring in the ICU before reaching brain death status and their impact on the number of organs retrieved have not been investigated. Lastly, the intensity of the therapeutic interventions used to achieve these goals, and certain management delays, have only been partially studied. Our hypothesis is that achieving a bundle of therapeutic goals, and the intensity of the interventions used to reach these goals, both before and after BDD, are associated with a greater number of organs retrieved.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2025

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 23, 2024

Completed
18 days until next milestone

First Posted

Study publicly available on registry

January 10, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

April 23, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2026

Completed
Last Updated

May 16, 2025

Status Verified

May 1, 2025

Enrollment Period

10 months

First QC Date

December 23, 2024

Last Update Submit

May 13, 2025

Conditions

Outcome Measures

Primary Outcomes (9)

  • Mean arterial pressure

    Mean arterial pressure (MAP) between 60 and 110 mmHg

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Central venous pressure

    Central venous pressure (CVP) between 4 and 12 mmHg

    Within 7 last days before brain death and before multi-organ retrieval

  • Left ventricular ejection fraction

    Left ventricular ejection fraction (LVEF) ≥ 50%

    Between admission to intensive care and brain death and before multi-organ retrieval

  • vasopressor

    Low doses and a single vasopressor. (≤10 µg/kg/min of dopamine or ≤60 µg/min of Neosynephrine or ≤10 µg/min of norepinephrine))

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Arterial pH

    Arterial pH between 7.3 and 7.5

    Between admission to intensive care and brain death and before multi-organ retrieval

  • PaO2/FiO2

    PaO2/FiO2 ≥ 300

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Sodium levels

    Sodium levels ≤ 155 mmol/L

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Diuresis

    Diuresis ≥ 0.5 mL/kg/h

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Blood glucose

    Blood glucose ≤ 1.5 g/L

    Between admission to intensive care and brain death and before multi-organ retrieval

Secondary Outcomes (12)

  • demographics of Brain dead

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Causes of neurological injury leading to brain death

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Timelines and durations of patient management before and after brain death

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Incidence of organ failures before and after brain death

    Between admission to intensive care and brain death and before multi-organ retrieval

  • Incidence of acute kidney failure before and after brain death

    Between admission to intensive care and brain death and before multi-organ retrieval

  • +7 more secondary outcomes

Study Arms (1)

Organ donation

Patients over 18 years of age, hospitalized in the ICU In a state of brain death No objection to organ donation during their lifetime

Other: No interventtion

Interventions

to enhance the understanding of the factors associated with the number of organs retrieved from patients admitted to the ICU for organ donation

Organ donation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients in a state of brain dead. Patients meeting the inclusion criteria from January 1, 2022, to December 31, 2024, will be included in the study.

You may qualify if:

  • Patients over 18 years of age, hospitalized in the ICU
  • In a state of brain death
  • No objection to organ donation during their lifetime
  • Patients with social security coverage

You may not qualify if:

  • Objection to the use of their data during their lifetime
  • Registration in the national refusal registry

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hôpital Saint-Louis, AP-HP

Paris, 75010, France

NOT YET RECRUITING

Hôpital Pitié Salpêtrière AP-HP

Paris, 75013, France

RECRUITING

Related Publications (6)

  • Malinoski DJ, Patel MS, Daly MC, Oley-Graybill C, Salim A; UNOS Region 5 DMG workgroup. The impact of meeting donor management goals on the number of organs transplanted per donor: results from the United Network for Organ Sharing Region 5 prospective donor management goals study. Crit Care Med. 2012 Oct;40(10):2773-80. doi: 10.1097/CCM.0b013e31825b252a.

    PMID: 22846779BACKGROUND
  • Oniscu GC, Rockell K, Martin DE. Challenges in undertaking research in transplantation. Lancet. 2025 Mar 1;405(10480):681-683. doi: 10.1016/S0140-6736(24)00931-0. Epub 2024 May 21. No abstract available.

    PMID: 38788740BACKGROUND
  • iomedecine, P. Chiffres 2022 de l'activité de prélèvement et de greffe d'organes et de tissus et Baromète 2023 sur la connaissance et la perception du don d'organes en France.

    BACKGROUND
  • Patel MS, De La Cruz S, Sally MB, Groat T, Malinoski DJ. Active Donor Management During the Hospital Phase of Care Is Associated with More Organs Transplanted per Donor. J Am Coll Surg. 2017 Oct;225(4):525-531. doi: 10.1016/j.jamcollsurg.2017.06.014. Epub 2017 Jul 21.

  • Bera KD, Shah A, English MR, Harvey D, Ploeg RJ. Optimisation of the organ donor and effects on transplanted organs: a narrative review on current practice and future directions. Anaesthesia. 2020 Sep;75(9):1191-1204. doi: 10.1111/anae.15037. Epub 2020 May 19.

  • Patel MS, Zatarain J, De La Cruz S, Sally MB, Ewing T, Crutchfield M, Enestvedt CK, Malinoski DJ. The impact of meeting donor management goals on the number of organs transplanted per expanded criteria donor: a prospective study from the UNOS Region 5 Donor Management Goals Workgroup. JAMA Surg. 2014 Sep;149(9):969-75. doi: 10.1001/jamasurg.2014.967.

MeSH Terms

Conditions

Brain Death

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesComaUnconsciousnessConsciousness DisordersNeurobehavioral ManifestationsNeurologic ManifestationsDeathPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 23, 2024

First Posted

January 10, 2025

Study Start

April 23, 2025

Primary Completion

February 15, 2026

Study Completion

February 15, 2026

Last Updated

May 16, 2025

Record last verified: 2025-05

Locations